共查询到19条相似文献,搜索用时 78 毫秒
1.
B群脑膜炎球菌的多糖抗原无免疫原性,而外膜蛋白则是有效免疫原。本文介绍了B群脑膜炎球菌的外膜蛋白(OMP)的分离方法、各类OMP抗原的生物学特性和控制基因,以及在菌苗研制中的应用。 相似文献
2.
目前获准上市的流脑疫苗主要有A群、A+C群脑膜炎球菌疫苗及A,C,W-135及Y群的四价脑膜炎球菌疫苗,B群脑膜炎球菌疫苗尚未研制成功。近年来,研究人员以疫苗外膜蛋白为基础,应用反向疫苗学技术对B群脑膜炎球菌疫苗进行了大量研究,现重点对B群脑膜炎球菌多组分疫苗的研究进展予以综述。 相似文献
3.
4.
A+C群脑膜炎球菌多糖疫苗稳定性研究 总被引:2,自引:1,他引:2
为确定A C群脑膜炎球菌多糖疫苗有效期。对该疫苗在不同储藏温度下的稳定性进行了系统研究,将C群多糖抗原放置在37℃,A C群多糖疫苗分别放置在2-8℃,37℃和56℃,定期取样,用琼脂糖CL-4B凝胶柱层析后,测定Kd值在0.5以前的多糖回收率,结果表明,C群多糖抗原在37℃保存9周,A C群多糖疫苗于2-8℃保存4年,37℃保存88周,56℃保存10个月,多糖抗原或多糖疫苗的Kd值小于0.4,多糖回收率大于75%,符合规程要求;因而A C群脑膜炎球菌多糖疫苗的有效期可定为在2-8℃储藏条件下3年6个月。 相似文献
5.
目的评价ACYW135群脑膜炎球菌多糖疫苗在昆明健康人群接种的免疫原性,为流脑防治策略提供依据。方法 2010年对昆明市2岁!3、岁!、4岁!、5岁!、6岁!、10岁!、≥15岁共7个年龄组分层随机抽取筛选出654名健康人,分别采集免前和免后1个月血清。用微量杀菌力试验(TTC法)分别检测血清中抗A、C、Y和W135群脑膜炎球菌杀菌抗体的水平。结果免后1个月抗A、C、Y和W135群脑膜炎球菌的杀菌抗体阳转率分别为96.99%、96.37%、88.43%和87.07%,抗A、C、Y和W135群膜炎球菌血清的杀菌抗体几何平均滴度(GMT)分别为1∶297.991、∶195.80、1∶72.74和1∶45.95。结论 ACYW135群脑膜炎球菌多糖疫苗在≥2岁以上的健康人群中有较好的免疫原性。 相似文献
6.
周祖木 《微生物学免疫学进展》2000,28(3):62-65
由B群脑膜炎球菌所致的侵袭性感染是许多国家发病和死亡的重要原因,控制脑膜炎球菌感染和疾病的重要挑战是研制预防B群脑膜炎球菌感染的菌苗。B群脑膜炎球菌多无免疫原性,故目前的研究试图主要针对该菌外膜蛋白或脂多糖产生的免疫反应,本文对B群脑膜炎球菌外膜囊菌苗在动物和人类的免疫反应进行了综述。 相似文献
7.
本章主要介绍疫苗发展前景中提到的A群、C群脑膜炎球菌结合疫苗和B群蛋白质疫苗。关于脑膜炎球菌疫苗发展史的综述发表于1995年。 相似文献
8.
9.
目的评价A群C群脑膜炎球菌结合疫苗原液和成品的稳定性。方法分别将A群、C群脑膜炎球菌结合疫苗原液及A群C群脑膜炎球菌结合疫苗各选取连续3批,分别放置于37℃、20~25℃和2~8℃3种温度下,在一定的时间取样进行主要项目测定,在关键时间点进行全面检测。结果 A群结合疫苗原液于2~8℃保存9个月,20~25℃保存4周,37℃保存4 d;C群结合疫苗原液于2~8℃保存9个月,20~25℃保存6个月,37℃保存4周;A群C群脑膜炎球菌结合疫苗于2~8℃保存2年3个月,20~25℃保存6个月,37℃可以保存9周;各项检测指标均符合质量标准的要求。结论在2~8℃条件下,A群、C群脑膜炎球菌结合疫苗原液存放6个月,A群C群脑膜炎球菌结合疫苗存放2年,其质量稳定。 相似文献
10.
采用薄膜过滤法对A群C群脑膜炎球菌多糖疫苗的无菌检查方法进行验证.结果表明,薄膜过滤法具有取样量大,操作简便,污染几率小,能确保检验结果的准确性、有效性和重现性,该方法适用于A群C群脑膜炎球菌多糖疫苗的无菌检查方法. 相似文献
11.
Hughes MJ Wilson R Moore JC Lane JD Dobson RJ Muckett P Younes Z Pribul P Topping A Feldman RG Santangelo JD 《FEMS microbiology letters》2003,222(2):263-271
Using an alkaline phosphatase-based genetic screening method, we identified a number of proteins that are potentially located on the outer surface of Group B streptococcus (Streptococcus agalactiae). In an enzyme-linked immunosorbent assay, antisera raised against two of the proteins, the streptococcal yutD homologue and a subunit of an ABC transporter, recognised clinically important serotypes of Group B streptococcus. In a neonatal rat model, purified IgG from the sera conferred significant levels of protection against a lethal challenge infection. The proteins identified show potential as protein subunit candidates for vaccines against Group B streptococcal disease in neonates. 相似文献
12.
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays 总被引:15,自引:0,他引:15
Grifantini R Bartolini E Muzzi A Draghi M Frigimelica E Berger J Ratti G Petracca R Galli G Agnusdei M Giuliani MM Santini L Brunelli B Tettelin H Rappuoli R Randazzo F Grandi G 《Nature biotechnology》2002,20(9):914-921
We have used DNA microarrays to follow Neisseria meningitidis serogroup B (MenB) gene regulation during interaction with human epithelial cells. Host-cell contact induced changes in the expression of 347 genes, more than 30% of which encode proteins with unknown function. The upregulated genes included transporters of iron, chloride, amino acids, and sulfate, many virulence factors, and the entire pathway of sulfur-containing amino acids. Approximately 40% of the 189 upregulated genes coded for peripherally located proteins, suggesting that cell contact promoted a substantial reorganization of the cell membrane. This was confirmed by fluorescence activated cell sorting (FACS) analysis on adhering bacteria using mouse sera against twelve adhesion-induced proteins. Of the 12 adhesion-induced surface antigens, 5 were able to induce bactericidal antibodies in mice, demonstrating that microarray technology is a valid approach for identifying new vaccine candidates and nicely complements other genome mining strategies used for vaccine discovery. 相似文献
13.
将C群脑膜炎球菌粗多糖的纯化改进为用1:1容量冷酚提取的生产工艺。结果表明,改进后的方法去除蛋白质效果同样能够达到《中国药典》2005版(三部)的要求,总体结果优于改进前。同时能扩大处理量而降低了生产成本,适合规模化生产。 相似文献
14.
A群奈瑟氏脑膜炎球菌荚膜多糖-破伤风类毒素结合疫苗的制备及其免疫原性研究 总被引:1,自引:0,他引:1
采用溴化氰(CNBr)活化多糖,以无水己二酸二肼(ADH)作为连接剂,1乙基13(3二甲基氨基丙基)碳化二亚胺(EDAC)为偶联剂制备A群奈瑟氏脑膜炎球菌荚膜多糖(GAMP)与破伤风类毒素(TT)的结合物,经皮下免疫NIH小鼠,用ELISA检测小鼠血清中抗GAMP及抗载体蛋白的IgG抗体水平。用补体介导的体外杀菌试验检测血清中GAMP抗体的杀菌活性。结果显示,实验中制备的多糖衍生物和多糖蛋白质结合物都具有GAMP抗原特异活性。结合物免疫小鼠后可诱生比多糖单独免疫更高水平的GAMP血清IgG抗体,并能形成免疫记忆,产生再次应答。结合物免疫小鼠所诱生的血清GAMP抗体较之多糖组具有更强的体外杀菌活性。表明此方法制备的结合物可获得优于多糖的、稳定的特异免疫原性。 相似文献
15.
Shigella flexneri is a gram-negative bacterium which causes the most communicable of bacterial dysenteries, shigellosis. Shigellosis causes 1.1 million deaths and over 164 million cases each year, with the majority of cases occurring in the children of developing nations. The pathogenesis of S. flexneri is based on the bacteria's ability to invade and replicate within the colonic epithelium, which results in severe inflammation and epithelial destruction. The molecular mechanisms used by S. flexneri to cross the epithelial barrier, evade the host's immune response and enter epithelial cells have been studied extensively in both in vitro and in vivo models. Consequently, numerous virulence factors essential to bacterial invasion, intercellular spread and the induction of inflammation have been identified in S. flexneri. The inflammation produced by the host has been implicated in both the destruction of the colonic epithelium and in controlling and containing the Shigella infection. The host's humoral response to S. flexneri also appears to be important in protecting the host, whilst the role of the cellular immune response remains unclear. The host's immune response to shigellosis is serotype-specific and protective against reinfection by the same serotype, making vaccination a possibility. Since the 1940s vaccines for S. flexneri have been developed with little success, however, the growing understanding of S. flexneri's pathogenesis and the host's immune response is assisting in the generation of more refined vaccine strategies. Current research encompasses a variety of vaccine types, which despite disparity in their efficacy and safety in humans represent promising progress in S. flexneri vaccine development. 相似文献
16.
A rat model was used to investigate maternal age-dependent resistance on group B Streptococcus (GBS)-induced mortality of the offspring. Offspring from young (first time) or older (repeat litters) dams were challenged with GBS. There was an approximate log difference in the dose of GBS required to cause identical levels of mortality in the two groups. The sera of the dams from both groups were analysed by whole-cell ELISA, and it was demonstrated that sera from the older dams possessed circulating IgG cross-reactive to GBS. Since IgG is transplacentally transferred, we conclude that this is the method of observed protection. 相似文献
17.
Experimental vaccine strategies for cancer immunotherapy 总被引:10,自引:0,他引:10
Recently, cancer immunotherapy has emerged as a therapeutic option for the management of cancer patients. This is based on the fact that our immune system, once activated, is capable of developing specific immunity against neoplastic but not normal cells. Increasing evidence suggests that cell-mediated immunity, particularly T-cell-mediated immunity, is important for the control of tumor cells. Several experimental vaccine strategies have been developed to enhance cell-mediated immunity against tumors. Some of these tumor vaccines have generated promising results in murine tumor systems. In addition, several phase I/II clinical trials using these vaccine strategies have shown extremely encouraging results in patients. In this review, we will discuss many of these promising cancer vaccine strategies. We will pay particular attention to the strategies employing dendritic cells, the central player for tumor vaccine development. 相似文献
18.
目的探讨CTAB不同的加入方法对A群脑膜炎球菌荚膜多糖分子大小的影响。方法采用分次加入手动搅拌和持续加入机械快速搅拌两种CTAB加入方法,纯化获得荚膜多糖粗糖,分别编为B组和C组。将两组荚膜多糖粗糖分别纯化获得精糖,分别编为D组和E组。以Sepharose CL-4B凝胶层析纯化获得荚膜多糖并检测其KD值。结果 B组荚膜多糖粗糖的KD值介于0.34~0.35之间,C组荚膜多糖粗糖的KD值介于0.03~0.05,进一步用苯酚纯化获得精糖后KD值D组介于0.34~0.36之间,E组介于0.22~0.28之间。两组相比KD值显著降低。结论CTAB的加入过程对A群脑膜炎球菌荚膜多糖的分子大小有明显的影响,CTAB沉淀时进行快速而充分的搅拌,纯化获得的荚膜多糖相对分子质量更大。 相似文献
19.
Mark W. Platt Joseph Scaletti Norberto CorreaJr. 《FEMS immunology and medical microbiology》1994,9(3):245-251
Abstract A Group B Streptococcus Type III (GBS) mutant which, when grown in Todd Hewitt broth (THB), does not produce any detectable capsule, produced a clearly visible polysaccharide capsule when grown in human serum. We isolated cytoplasmic membranes from GBS and separated the component membrane proteins by polyacrylamide gel electrophoresis. A significant change in membrane composition was found during growth in human serum. Several unique proteins were produced on serum growth and there was both up- and down-regulation of other proteins. We measured the intracellular levels of sialic acid for a variety of GBS serotype III isolates. Interestingly, while there was little difference between the intracellular sialic levels of most isolates, the sialic acid level of COH31-15 grown in THB was over 100% higher than that of any other isolate. When grown in serum this pool was reduced to a level similar to that in other strains. The concentration of bacterial cell sialic acid was directly correlated with the sialic acid content of the serum. Exogenous sialic acid content, in concert with other serum factors, plays a role in determining the capsular size in GBS. 相似文献